The UK company is the latest to join ranks of AI-focused drugmakers attracting venture capital.

The researcher who invented Viagra and a colleague at Cambridge University have become the latest to join the ranks of drug developers using artificial intelligence and attracting attention from venture capitalists.

Cambridge, UK-based Healx said Thursday that it had raised $10 million in a Series A funding round, led by London-based venture capital firm Balderton Capital. Fellow British venture capital firm Amadeus Capital Partners and Jonathan Milner – founder of life sciences supplier Abcam – also participated. Cambridge Rare Diseases Network founder Tim Guilliams and David Brown – who invented Pfizer’s erectile dysfunction drug, which is now available as a generic – are the founders of Healx.

The company uses the HealNet database, which maps more than 1 billion disease, patient and drug interactions and was built and maintained using machine learning techniques. The company plans to use the Series A round to expand its team of software engineers, data scientists, pharmacologists and drug development researchers.

Read more at medcitynews.com

Image Credit:  Alias Studio Sydney

News This Week

Visualizing the Healthtech Revolution

Imagine being a patient in the early 19th century, when all ailments were considered “humors” to be ejected from the body. To restore balance, various techniques such as diets, natural herbs, or bloodletting with [...]

Nano-bot can probe inside human cells

University of Toronto Engineering researchers have built a set of magnetic 'tweezers' that can position a nano-scale bead inside a human cell in three dimensions with unprecedented precision. The nano-bot has already been used [...]